[Federal Register Volume 74, Number 157 (Monday, August 17, 2009)]
[Notices]
[Page 41455]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-19487]


=======================================================================
-----------------------------------------------------------------------

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice (09-072)]


Notice of Intent To Grant Partially Exclusive License

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of intent to grant partially exclusive license.

-----------------------------------------------------------------------

SUMMARY: This notice is issued in accordance with 35 U.S.C. 209(c)(1) 
and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to 
grant an exclusive license worldwide to practice the invention 
described and claimed in U.S. Patent No. 7,094,045, 
entitled``Microencapsulation System and Method'', U.S. Patent No. 
7,295,309, entitled ``Microparticle Analysis System and Method'' to 
NuVue Therapeutics, Inc. (formerly known as Critical Care Innovations, 
Inc.), having its principal place of business in Fairfax, Virginia. The 
fields of use are for both clinical and veterinary applications in the 
production and applications of microcapsules and microencapsulation of 
all cyto-toxic anti-cancer drugs. Also included are externally-
triggered microcapsules including the use of ultrasound and magnetic 
flux triggering technologies, in situ activation inside microcapsules, 
cell encapsulation, and urokinase and DNA measurement of metastasis for 
diagnostic testing. The patent rights in these inventions have been 
assigned to the United States of America as represented by the 
Administrator of the National Aeronautics and Space Administration. The 
prospective partially exclusive license will comply with the terms and 
conditions of 35 U.S.C. 209 and 37 CFR 404.7.

DATES: The prospective partially exclusive license may be granted 
unless, within fifteen (15) days from the date of this published 
notice, NASA receives written objections including evidence and 
argument that establish that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. 
Competing applications completed and received by NASA within fifteen 
(15) days of the date of this published notice will also be treated as 
objections to the grant of the contemplated exclusive license.
    Objections submitted in response to this notice will not be made 
available to the public for inspection and, to the extent permitted by 
law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

ADDRESSES: Objections relating to the prospective license may be 
submitted to Patent Counsel, Office of Chief Counsel, Mail Code AL, 
2101 NASA Parkway, Houston, TX 77058, (281) 483-4871; (281) 483-6936 
[Facsimile].

FOR FURTHER INFORMATION CONTACT: Theodore U. Ro, Patent Attorney, 
Office of Chief Counsel, Johnson Space Center, Mail Code AL, 2101 NASA 
Parkway, Houston, TX 77058, (281)244-7148; (281)483-6936 [Facsimile]. 
Information about other NASA inventions available for licensing can be 
found online at http://technology.nasa.gov/.

    Dated: August 7, 2009.
Richard W. Sherman,
Deputy General Counsel.
[FR Doc. E9-19487 Filed 8-14-09; 8:45 am]
BILLING CODE P